Evaluation of a Standard Dietary Regimen Combined with Heat-Inactivated Lactobacillus gasseri HM1, Lactoferrin-Producing HM1, and Their Sonication-Inactivated Variants in the Management of Metabolic Disorders in an Obesity Mouse Model. 2024

Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung 402202, Taiwan.

This study investigated the impact of incorporating various inactivated probiotic formulations, with or without recombinant lactoferrin (LF) expression, into a standard chow diet on metabolic-related disorders in obese mice. After inducing obesity through a 13-week high-fat diet followed by a standard chow diet, mice received daily oral administrations of different probiotics for 6 weeks using the oral gavage approach. These probiotic formulations consisted of a placebo (MRS), heat-inactivated Lactobacillus gasseri HM1 (HK-HM1), heat-killed LF-expression HM1 (HK-HM1/LF), sonication-killed HM1 (SK-HM1), and sonication-killed LF-expression HM1 (SK-HM1/LF). The study successfully induced obesity, resulting in worsened glucose tolerance and insulin sensitivity. Interestingly, the regular diet alone improved glucose tolerance, and the addition of inactivated probiotics further enhanced this effect, with SK-HM1/LF demonstrating the most noticeable improvement. However, while regular dietary intervention alone improved insulin sensitivity, probiotic supplementation did not provide additional benefits in this aspect. Inflammation in perirenal and epididymal fat tissues was partially alleviated by the regular diet and further improved by probiotics, particularly by SK-HM1, which showed the most significant reduction. Additionally, HK-HM1 and HK-HM1/LF supplements could contribute to the improvement of serum total triglycerides or total cholesterol, respectively. Overall, incorporating inactivated probiotics into a regular diet may enhance metabolic indices, and recombinant LF may offer potential benefits for improving glucose tolerance.

UI MeSH Term Description Entries

Related Publications

Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
January 2013, The British journal of nutrition,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
January 2020, Biomedical research (Tokyo, Japan),
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
February 2021, Beneficial microbes,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
September 2006, Journal of proteome research,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
January 2024, Metabolites,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
December 2009, The Psychiatric clinics of North America,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
September 2017, Iranian journal of medical sciences,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
November 2023, Journal of personalized medicine,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
January 2019, BMC microbiology,
Wei-Chen Shiu, and Zhen-Shu Liu, and Bo-Yuan Chen, and Yu-We Ku, and Po-Wen Chen
May 2022, Pathogens (Basel, Switzerland),
Copied contents to your clipboard!